An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP
Phase of Trial: Phase III
Latest Information Update: 26 Dec 2018
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Therapeutic Use
- 18 Dec 2018 Status changed from active, no longer recruiting to completed.
- 03 Oct 2018 Planned End Date changed from 31 Aug 2018 to 31 Oct 2018.
- 18 Jul 2018 Planned End Date changed from 31 Dec 2019 to 31 Aug 2018.